GuerbetXPAR:GBT -0.54%68 EBITDA Margin % is 6.49% as of Dec. 2025, which is 50% below its 10-year median of 13.10. GuruFocus rates XPAR:GBT with a GF Score™ of 68/100 and a GF Value™ of €19.65 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Guerbet ranks better than 53.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Guerbet's EBITDA for the
six
months ended in Dec. 2025 was €26.5 Mil. Guerbet's Revenue for the
six
months ended in Dec. 2025 was €407.3 Mil. Therefore, Guerbet's EBITDA margin for the quarter that ended in Dec. 2025 was 6.49%.
Guerbet (XPAR:GBT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Guerbet EBITDA Margin % Related Terms
Guerbet EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Guerbet's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:GBT vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Guerbet's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guerbet EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Guerbet's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Guerbet's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guerbet (XPAR:GBT) has a EBITDA Margin % of 6.49% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guerbet and its competitors. This is 50% below median its historical median of 13.10. Over the past decade, Guerbet's EBITDA Margin % has ranged from 9.09 to 15.56. According to the industry distribution chart, Guerbet ranks #380 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 46.6%.
Is Guerbet's EBITDA Margin % too high?
Guerbet's current EBITDA Margin % of 6.49% is 50% below median its 10-year median of 13.10. Over the past 10 years, this metric has ranged from a low of 9.09 to a high of 15.56. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Guerbet's value of 6.49% is 13.2% below this industry median. Based on the distribution chart, Guerbet ranks #380 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Guerbet has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Guerbet's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Guerbet ranks #380 out of 816 companies for EBITDA Margin %. This puts Guerbet in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Guerbet's value of 6.49% is 13.2% below this benchmark. Historically, Guerbet's own EBITDA Margin % has ranged from 9.09 to 15.56 over the past decade. While the company's 10-year median is 13.10 vs. the industry median of 7.48, Guerbet has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guerbet's current EBITDA Margin % of 6.49% is 13.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guerbet and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guerbet's current EBITDA Margin % is 6.49%, which is 50% below median its own 10-year median of 13.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guerbet stock overvalued right now?
Based on GuruFocus' analysis, Guerbet (XPAR:GBT) is currently considered Possible Value Trap. The stock's GF Value™ is €19.65, compared to a current price of €9.18 — trading 53.3% below its estimated fair value. The current EBITDA Margin % is 6.49%, which is 50% below median its 10-year median of 13.10 and 13.2% below the Medical Devices & Instruments industry median of 7.48. Guerbet's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Guerbet (XPAR:GBT), the current EBITDA Margin % is 6.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guerbet (XPAR:GBT) Overvalued in 2026?
Based on GuruFocus' analysis, Guerbet stock appears to be undervalued.
The current stock price of €9.18 is trading 53.3% below its estimated GF Value™ of €19.65.
GuruFocus considers Guerbet to be Possible Value Trap.
Key valuation signals for XPAR:GBT:
EBITDA Margin %: 6.49% (50% below median its 10-year median of 13.10)
GF Value™: €19.65 vs. price of €9.18 (53.3% below fair value)
Industry Position: 13.2% below the Medical Devices & Instruments median (#380 of 816)
No single metric tells the full story. See the XPAR:GBT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
68GF Score
Get the complete analysis for XPAR:GBT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:GBT has been successfully added to your 
